Broad-spectrum antivirals are powerful weapons against dangerous
viruses where no specific therapy exists, as in the case of the
ongoing SARS-CoV-2 pandemic. We discovered that a lysine- and
arginine-specific supramolecular ligand (CLR01) destroys
enveloped viruses, including HIV, Ebola, and Zika virus, and
remodels amyloid fibrils in semen that promote viral infection.
Yet, it is unknown how CLR01 exerts these two distinct
therapeutic activities. Here, we delineate a novel mechanism of
antiviral activity by studying the activity of tweezer variants:
the “phosphate tweezer” CLR01, a
“carboxylate tweezer” CLR05, and a
“phosphate clip” PC. Lysine complexation inside
the tweezer cavity is needed to antagonize amyloidogenesis and
is only achieved by CLR01. Importantly, CLR01 and CLR05 but not
PC form closed inclusion complexes with lipid head groups of
viral membranes, thereby altering lipid orientation and
increasing surface tension. This process disrupts viral
envelopes and diminishes infectivity but leaves cellular
membranes intact. Consequently, CLR01 and CLR05 display broad
antiviral activity against all enveloped viruses tested,
including herpesviruses, Measles virus, influenza, and
SARS-CoV-2. Based on our mechanistic insights, we potentiated
the antiviral, membrane-disrupting activity of CLR01 by
introducing aliphatic ester arms into each phosphate group to
act as lipid anchors that promote membrane targeting. The most
potent ester modifications harbored unbranched C4 units, which
engendered tweezers that were approximately one order of
magnitude more effective than CLR01 and nontoxic. Thus, we
establish the mechanistic basis of viral envelope disruption by
specific tweezers and establish a new class of potential
broad-spectrum antivirals with enhanced activity.